Erratum: Low-Dose Liver-Targeted Gene Therapy for Pompe Disease Enhances Therapeutic Efficacy of ERT via Immune Tolerance Induction (Low-Dose Liver-Targeted Gene Therapy for Pompe Disease Enhances Therapeutic Efficacy of ERT via Immune Tolerance Induction (2017) 4 (126–136), (S2329050117300049), (10.1016/j.omtm.2016.12.010))
Publication
, Journal Article
Han, SO; Ronzitti, G; Arnson, B; Leborgne, C; Li, S; Mingozzi, F; Koeberl, D
Published in: Molecular Therapy Methods and Clinical Development
June 14, 2019
(Molecular Therapy - Methods & Clinical Development 4, 126–136; March 17, 2017) An incorrect version of Figure 1E appeared in the published article due to an error in the calculation of plasma GAA. The correct figure appears below. [Figure Presented]
Duke Scholars
Published In
Molecular Therapy Methods and Clinical Development
DOI
EISSN
2329-0501
Publication Date
June 14, 2019
Volume
13
Start / End Page
431
Related Subject Headings
- 3206 Medical biotechnology
Citation
APA
Chicago
ICMJE
MLA
NLM
Han, S. O., Ronzitti, G., Arnson, B., Leborgne, C., Li, S., Mingozzi, F., & Koeberl, D. (2019). Erratum: Low-Dose Liver-Targeted Gene Therapy for Pompe Disease Enhances Therapeutic Efficacy of ERT via Immune Tolerance Induction (Low-Dose Liver-Targeted Gene Therapy for Pompe Disease Enhances Therapeutic Efficacy of ERT via Immune Tolerance Induction (2017) 4 (126–136), (S2329050117300049), (10.1016/j.omtm.2016.12.010)). Molecular Therapy Methods and Clinical Development, 13, 431. https://doi.org/10.1016/j.omtm.2019.04.005
Han, S. O., G. Ronzitti, B. Arnson, C. Leborgne, S. Li, F. Mingozzi, and D. Koeberl. “Erratum: Low-Dose Liver-Targeted Gene Therapy for Pompe Disease Enhances Therapeutic Efficacy of ERT via Immune Tolerance Induction (Low-Dose Liver-Targeted Gene Therapy for Pompe Disease Enhances Therapeutic Efficacy of ERT via Immune Tolerance Induction (2017) 4 (126–136), (S2329050117300049), (10.1016/j.omtm.2016.12.010)).” Molecular Therapy Methods and Clinical Development 13 (June 14, 2019): 431. https://doi.org/10.1016/j.omtm.2019.04.005.
Han SO, Ronzitti G, Arnson B, Leborgne C, Li S, Mingozzi F, et al. Erratum: Low-Dose Liver-Targeted Gene Therapy for Pompe Disease Enhances Therapeutic Efficacy of ERT via Immune Tolerance Induction (Low-Dose Liver-Targeted Gene Therapy for Pompe Disease Enhances Therapeutic Efficacy of ERT via Immune Tolerance Induction (2017) 4 (126–136), (S2329050117300049), (10.1016/j.omtm.2016.12.010)). Molecular Therapy Methods and Clinical Development. 2019 Jun 14;13:431.
Han, S. O., et al. “Erratum: Low-Dose Liver-Targeted Gene Therapy for Pompe Disease Enhances Therapeutic Efficacy of ERT via Immune Tolerance Induction (Low-Dose Liver-Targeted Gene Therapy for Pompe Disease Enhances Therapeutic Efficacy of ERT via Immune Tolerance Induction (2017) 4 (126–136), (S2329050117300049), (10.1016/j.omtm.2016.12.010)).” Molecular Therapy Methods and Clinical Development, vol. 13, June 2019, p. 431. Scopus, doi:10.1016/j.omtm.2019.04.005.
Han SO, Ronzitti G, Arnson B, Leborgne C, Li S, Mingozzi F, Koeberl D. Erratum: Low-Dose Liver-Targeted Gene Therapy for Pompe Disease Enhances Therapeutic Efficacy of ERT via Immune Tolerance Induction (Low-Dose Liver-Targeted Gene Therapy for Pompe Disease Enhances Therapeutic Efficacy of ERT via Immune Tolerance Induction (2017) 4 (126–136), (S2329050117300049), (10.1016/j.omtm.2016.12.010)). Molecular Therapy Methods and Clinical Development. 2019 Jun 14;13:431.
Published In
Molecular Therapy Methods and Clinical Development
DOI
EISSN
2329-0501
Publication Date
June 14, 2019
Volume
13
Start / End Page
431
Related Subject Headings
- 3206 Medical biotechnology